Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program

• Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020.

• GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment.

• It is currently in Phase 1 development for solid tumors.

• Jounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and commercialization of GS-1811 globally.

• Gilead expects the transaction with Jounce to reduce its GAAP and non-GAAP 2022 EPS by approximately $0.04.

• Jounce will no longer be entitled to receive the remaining contingent payments of up to $645 million in milestones and high single-digit to mid-teens royalties based upon worldwide sales under the original license agreement.

• Price Action: JNCE shares are up 68.2% at $1.24 during the premarket session on the last check Wednesday.

See more from Benzinga

• Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial

• China Relaxes Approval Of Imported Games, Google Workers Dread Mass Layoffs, FDA Working On Regulating Pathways For Cannabis: Today's Top Stories

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.